Targeting fructokinase, endogenous fructose production and purine degradation for the prevention and treatment of hereditary fructose intolerance

针对果糖激酶、内源性果糖产生和嘌呤降解来预防和治疗遗传性果糖不耐受

基本信息

项目摘要

 DESCRIPTION (provided by applicant): Dietary intake of sugars containing fructose has dramatically increased in our society with one-sixth of the population eating 25% of their diet or more. While attempts to reduce sugar intake are now recommended, it is very difficult to avoid exposure to HFCS and sucrose in today's culture. One group that suffers from the widespread use of added sugars are individuals with Hereditary Fructose Intolerance (HFI), an autosomal recessive whose subjects develop severe reactions following fructose ingestion, with abdominal pain, vomiting, diarrhea, symptomatic hypoglycemia, hyperuricemia, and even death in children. Fructose metabolism is initiated by two enzymes, fructokinase that phosphorylates fructose to fructose-1- phosphate causing ATP depletion and uric acid generation, and aldolase b that further splits the fructose-1- phosphate molecule into dihydroacetone phosphate and glyceraldehyde. HFI is caused by the mutation in aldolase B leading to accumulation of fructose-1-phosphate, marked ATP depletion and uric acid generation following fructose ingestion that is much greater than that observed in normal individuals. Our preliminary data in aldolase b deficient mice suggest that upon exposure to fructose -in diet or endogenously produced-, its deficiency is associated with fructokinase hyperactivation, growth retardation, severe hypoglycemia, liver/intestinal injury and death which are completely blocked when fructokinase is inhibited. Of interest, the deleterious effects observed in aldolase b deficient mice are exacerbated when mice are hyperuricemic suggesting an important deleterious role of uric acid in the pathogenesis of HFI. These observation led us to our overall hypothesis that the blockade of fructose metabolism to fructose-1- phosphate protects against HFI in subjects with aldolase b deficiency. Specifically, we propose that 1) fructokinase knockout mice with aldolase b deficiency will not develop HFI upon exposure to fructose, 2) the blockade of endogenous fructose production by inhibition of aldose reductase and the polyol pathway is clinically relevant for people with aldolase b deficiency and 3) lowering uric acid production and accumulation is an important therapeutic approach in the prevention and treatment of HFI. The studies proposed in this application are clinically relevant as they will provide insights into future therapies (targeting fructokinase, aldose reductase, AMP deaminase and/or xanthine oxidase) for this disease in which the only treatment (avoidance of fructose) has become almost impossible in our society. The applicant will count with an excellent group of collaborators that include Drs. Dean Tolan -a world expert in clinical hereditary fructose intolerance- and Richard Johnson -a renowned scientist in the field of sugar and fructose metabolism-. This award will allow the applicant as an early stage investigator (ESI) to develop the skills necessary and the financial needs to fully become an independent scientist and will provide for intellectual development through both didactic programs and by facilitating interactions with a variety of researchers in different departments.
 描述(由申请人提供):在我们的社会中,含果糖的糖的膳食摄入量急剧增加,六分之一的人口食用其饮食的25%或更多。虽然现在建议尝试减少糖的摄入量,但在今天的文化中,很难避免接触HFCS和蔗糖。广泛使用添加糖的一个群体是患有遗传性果糖不耐受(HFI)的个体,HFI是一种常染色体隐性遗传,其受试者在摄入果糖后发生严重反应,包括腹痛、呕吐、腹泻、症状性低血糖、高尿酸血症,甚至儿童死亡。果糖代谢由两种酶启动,果糖激酶将果糖磷酸化为果糖-1-磷酸,导致ATP消耗和尿酸生成,而醛缩酶B将果糖-1-磷酸分子进一步分解为磷酸二氢丙酮和甘油醛。HFI是由醛缩酶B的突变引起的,导致果糖-1-磷酸的积累,显著的ATP消耗和果糖摄入后尿酸的产生,其比在正常个体中观察到的要大得多。我们在醛缩酶B缺陷小鼠中的初步数据表明,在暴露于果糖时-在饮食中或内源性产生-,其缺陷与果糖激酶过度活化、生长迟缓、严重低血糖、肝/肠损伤和死亡相关,当果糖激酶被抑制时,这些损伤和死亡被完全阻断。值得注意的是,当小鼠高尿酸血症时,在醛缩酶B缺陷小鼠中观察到的有害作用加剧,表明尿酸在HFI发病机制中的重要有害作用。这些观察结果使我们得出了我们的总体假设,即阻断果糖代谢为果糖-1-磷酸可保护醛缩酶B缺乏的受试者免受HFI。具体而言,我们提出1)果糖激酶敲除小鼠与醛缩酶B缺乏不会发展HFI后暴露于果糖,2)通过抑制醛糖还原酶和多元醇途径阻断内源性果糖生产是临床相关的 对于患有醛缩酶B缺乏症的人,以及3)降低尿酸产生和积累是预防和治疗HFI的重要治疗方法。本申请中提出的研究具有临床相关性,因为它们将为这种疾病的未来疗法(靶向果糖激酶、醛糖还原酶、AMP脱氨酶和/或黄嘌呤氧化酶)提供见解,在这种疾病中,唯一的治疗(避免果糖)在我们的社会中几乎是不可能的。申请人将与包括Dean Tolan博士在内的优秀合作者团队一起计数-临床遗传性果糖不耐受的世界专家-和Richard约翰逊-糖和果糖代谢领域的着名科学家-。该奖项将允许申请人作为早期研究者(ESI)发展必要的技能和财务需求,以完全成为一名独立的科学家,并将通过教学计划和促进与不同部门的各种研究人员的互动来提供智力发展。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Miguel Angel Lanaspa Garcia其他文献

Miguel Angel Lanaspa Garcia的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Miguel Angel Lanaspa Garcia', 18)}}的其他基金

A Novel Role for Vasopressin in Fructose-Induced Metabolic Syndrome
加压素在果糖诱导的代谢综合征中的新作用
  • 批准号:
    10548048
  • 财政年份:
    2020
  • 资助金额:
    $ 23.06万
  • 项目类别:
A Novel Role for Vasopressin in Fructose-Induced Metabolic Syndrome
加压素在果糖诱导的代谢综合征中的新作用
  • 批准号:
    10756244
  • 财政年份:
    2020
  • 资助金额:
    $ 23.06万
  • 项目类别:
Targeting fructokinase, endogenous fructose production and purine degradation for the prevention and treatment of hereditary fructose intolerance
针对果糖激酶、内源性果糖产生和嘌呤降解来预防和治疗遗传性果糖不耐受
  • 批准号:
    10543664
  • 财政年份:
    2016
  • 资助金额:
    $ 23.06万
  • 项目类别:
A novel Role for endogenous fructose production and metabolism in the pathogenesis of contrast-induced nephropathy
内源性果糖产生和代谢在造影剂肾病发病机制中的新作用
  • 批准号:
    9015439
  • 财政年份:
    2015
  • 资助金额:
    $ 23.06万
  • 项目类别:
A novel role for endogenous fructose in ischemic acute kidney injury
内源性果糖在缺血性急性肾损伤中的新作用
  • 批准号:
    8690049
  • 财政年份:
    2012
  • 资助金额:
    $ 23.06万
  • 项目类别:
A novel role for endogenous fructose in ischemic acute kidney injury
内源性果糖在缺血性急性肾损伤中的新作用
  • 批准号:
    8511623
  • 财政年份:
    2012
  • 资助金额:
    $ 23.06万
  • 项目类别:
A novel role for endogenous fructose in ischemic acute kidney injury
内源性果糖在缺血性急性肾损伤中的新作用
  • 批准号:
    9114568
  • 财政年份:
    2012
  • 资助金额:
    $ 23.06万
  • 项目类别:
A novel role for endogenous fructose in ischemic acute kidney injury
内源性果糖在缺血性急性肾损伤中的新作用
  • 批准号:
    8352397
  • 财政年份:
    2012
  • 资助金额:
    $ 23.06万
  • 项目类别:

相似海外基金

Disrupted sleep architecture in adolescents with functional abdominal pain disorders
患有功能性腹痛疾病的青少年的睡眠结构被破坏
  • 批准号:
    10641146
  • 财政年份:
    2023
  • 资助金额:
    $ 23.06万
  • 项目类别:
Development and Testing of an Intervention to Facilitate Shared Decision-Making in Pediatric Patients with Abdominal Pain Presenting to the Community Emergency Department Setting
开发和测试一种干预措施,以促进社区急诊科就诊的腹痛儿科患者共同决策
  • 批准号:
    10723374
  • 财政年份:
    2023
  • 资助金额:
    $ 23.06万
  • 项目类别:
Abdominal Pain in Older Patients in Emergency Departments
急诊科老年患者的腹痛
  • 批准号:
    10739136
  • 财政年份:
    2023
  • 资助金额:
    $ 23.06万
  • 项目类别:
Evaluation of abdominal pain after mucosal healing in patients with inflammatory bowel disease -comprehensive analysis of HPA axis-
炎症性肠病患者黏膜愈合后腹痛评价-HPA轴综合分析-
  • 批准号:
    22K16013
  • 财政年份:
    2022
  • 资助金额:
    $ 23.06万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Randomized controlled trial of an internet-based prevention intervention for young children at-risk for functional abdominal pain
针对有功能性腹痛风险的幼儿进行基于互联网的预防干预的随机对照试验
  • 批准号:
    10387725
  • 财政年份:
    2022
  • 资助金额:
    $ 23.06万
  • 项目类别:
Randomized controlled trial of an internet-based prevention intervention for young children at-risk for functional abdominal pain
针对有功能性腹痛风险的幼儿进行基于互联网的预防干预的随机对照试验
  • 批准号:
    10608073
  • 财政年份:
    2022
  • 资助金额:
    $ 23.06万
  • 项目类别:
Novel microbial driven histamine pathways underlying chronic abdominal pain
慢性腹痛背后的新型微生物驱动组胺途径
  • 批准号:
    453255
  • 财政年份:
    2021
  • 资助金额:
    $ 23.06万
  • 项目类别:
    Operating Grants
Home-based transcutaneous electrical acustimulation for abdominal pain
家庭经皮电针治疗腹痛
  • 批准号:
    10619029
  • 财政年份:
    2020
  • 资助金额:
    $ 23.06万
  • 项目类别:
Home-based transcutaneous electrical acustimulation for abdominal pain
家庭经皮电针治疗腹痛
  • 批准号:
    10045379
  • 财政年份:
    2020
  • 资助金额:
    $ 23.06万
  • 项目类别:
Home-based transcutaneous electrical acustimulation for abdominal pain
家庭经皮电针治疗腹痛
  • 批准号:
    10685484
  • 财政年份:
    2020
  • 资助金额:
    $ 23.06万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了